<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-26519" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Paclitaxel</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Awosika</surname>
            <given-names>Ayoola O.</given-names>
          </name>
          <aff>University of Illinois College of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Farrar</surname>
            <given-names>Maela C.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jacobs</surname>
            <given-names>Tibb F.</given-names>
          </name>
          <aff>University of Louisiana Monroe</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ayoola Awosika declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Maela Farrar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tibb Jacobs declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>18</day>
          <month>11</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-26519.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">The field of oncology is in a constant state of evolution and is driven by ongoing research discoveries and advancements in treatment approaches. Paclitaxel belongs to the category of chemotherapeutic agents and is utilized as a treatment for various types of cancer.&#x000a0; Indications for using paclitaxel encompass a range of cancers,&#x000a0;including breast, ovarian, bladder, lung, prostate, melanoma, esophageal, Kaposi sarcoma, and various other solid tumors. This therapeutic review provides an overview of paclitaxel's indications, mechanisms of action at the cellular level, role in inhibiting cancer cell growth, essential information on dosing regimens, infusion protocols, methods of administration, and contraindications, as well as the importance of monitoring patients undergoing paclitaxel therapy.</p>
        <p>A comprehensive understanding&#x000a0;of paclitaxel's potential adverse effects is crucial to managing hematological toxicities, peripheral neuropathy, gastrointestinal disturbances, and hypersensitivity reactions to ensure patient safety and quality of life. Essentially, this approach will aid healthcare practitioners in staying up-to-date with the latest clinical trials and research findings related to paclitaxel. Understanding new formulations and emerging indications and adopting a patient-centered approach, considering factors such as patient characteristics, disease stage, and coexisting conditions, are&#x000a0;essential when administering paclitaxel.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Differentiate between the mechanisms of action of paclitaxel and other chemotherapeutic agents, allowing for informed treatment selection.</p></list-item><list-item><p>Apply knowledge of emerging indications and resistance mechanisms to optimize paclitaxel-based treatment strategies for cancer patients.</p></list-item><list-item><p>Identify appropriate indications for paclitaxel therapy in treating various malignancies, considering cancer type, stage, and patient-specific factors.</p></list-item><list-item><p>Collaborate with an interprofessional healthcare team to coordinate paclitaxel therapy, evaluate treatment response, and enhance comprehensive cancer care plans for patients.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26519&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26519">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-26519.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Paclitaxel, initially named taxol, is a naturally occurring diterpenoid compound extracted from the Pacific yew tree, <italic toggle="yes">Taxus brevifolia</italic>. The discovery of paclitaxel can be credited to the research endeavors of the National Cancer Institute (NCI) during the late 1960s and early 1970s. Scientists were conducting screenings of plant extracts in search of potential anticancer agents when they discovered the distinctive cytotoxic properties of paclitaxel against cancer cells.&#x000a0;The compound's ability to inhibit microtubule depolymerization, leading to cell cycle arrest and apoptosis, intrigued researchers and paved the way for extensive investigation.&#x000a0;</p>
        <p>
<bold>History of&#x000a0;Paclitaxel's Phases of Clinical Trials and Development</bold>
</p>
        <p>During the mid-1980s, early-phase clinical trials were conducted to evaluate paclitaxel's safety, dosing, and pharmacokinetics in cancer patients. Encouraging positive outcomes led to the advancement into subsequent phases of clinical development. In the late 1980s and early 1990s, phase&#x000a0;2 trials demonstrated promising antitumor activity of paclitaxel in various solid tumors, including ovarian, breast, and lung cancers. Large-scale randomized phase 3 trials compared paclitaxel-based treatment regimens with standard chemotherapy or best supportive care across various cancer types. The results revealed significant improvements in response rates, progression-free survival, and overall survival among patients receiving paclitaxel-based therapies.&#x000a0;</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>The U.S. Food and Drug Administration (FDA) granted accelerated approval for paclitaxel in 1992 to treat refractory ovarian cancer. Subsequently, paclitaxel also received complete approval as the first-line treatment option for ovarian cancer. Over the years, the FDA extended paclitaxel's indications to include breast cancer, non-small cell lung cancer (NSCLC), and Kaposi sarcoma.&#x000a0;</p>
        <table-wrap id="article-26519.table0" position="float" orientation="portrait">
          <table style="width: 790px;" border="1" cellspacing="1" cellpadding="5">
            <tbody>
              <tr>
                <td style="width: 170.49px;" rowspan="1" colspan="1">
<bold>FDA-Approved Indications</bold>
</td>
                <td style="padding-left: 210px; width: 430.51px;" rowspan="1" colspan="1">&#x000a0;<bold>Treatments</bold></td>
              </tr>
              <tr>
                <td style="width: 170.49px;" rowspan="1" colspan="1">Ovarian cancer</td>
                <td style="width: 430.51px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>First-line treatment: Paclitaxel, when combined with cisplatin or carboplatin, is approved for treating advanced ovarian cancer after initial surgery.<xref ref-type="bibr" rid="article-26519.r1">[1]</xref><xref ref-type="bibr" rid="article-26519.r2">[2]</xref></p></list-item><list-item><p>Recurrent or refractory disease: Paclitaxel can be used either as a standalone treatment or in combination with other chemotherapeutic agents for recurrent or refractory ovarian cancer.<xref ref-type="bibr" rid="article-26519.r3">[3]</xref><xref ref-type="bibr" rid="article-26519.r4">[4]</xref></p></list-item></list>
</td>
              </tr>
              <tr>
                <td style="width: 170.49px;" rowspan="1" colspan="1">Breast cancer</td>
                <td style="width: 430.51px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Adjuvant treatment: Paclitaxel is recommended as an adjuvant treatment for individuals with early-stage breast cancer after completing standard chemotherapy with doxorubicin and cyclophosphamide.<xref ref-type="bibr" rid="article-26519.r5">[5]</xref></p></list-item><list-item><p>Metastatic breast cancer: Paclitaxel is approved for treating metastatic breast cancer either as a standalone treatment or in combination with other chemotherapeutic agents such as trastuzumab or bevacizumab.<xref ref-type="bibr" rid="article-26519.r6">[6]</xref><xref ref-type="bibr" rid="article-26519.r7">[7]</xref><xref ref-type="bibr" rid="article-26519.r8">[8]</xref><xref ref-type="bibr" rid="article-26519.r6">[6]</xref></p></list-item></list>
</td>
              </tr>
              <tr>
                <td style="width: 170.49px;" rowspan="1" colspan="1">NSCLC</td>
                <td style="width: 430.51px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>First-line treatment: Paclitaxel, in combination with cisplatin or carboplatin, is used as a first-line treatment option for individuals with NSCLC who are not suitable candidates for surgery.<xref ref-type="bibr" rid="article-26519.r9">[9]</xref></p></list-item><list-item><p>Second-line treatment: Paclitaxel can be considered a second-line treatment option for individuals with advanced NSCLC after failure of initial therapy.</p></list-item></list>
</td>
              </tr>
              <tr>
                <td style="width: 170.49px;" rowspan="1" colspan="1">AIDS-related Kaposi sarcoma</td>
                <td style="width: 430.51px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Second-line&#x000a0;treatment: Paclitaxel is used as a second-line therapy for patients experiencing disease progression despite prior systemic chemotherapy or for those unable to tolerate other treatments.<xref ref-type="bibr" rid="article-26519.r10">[10]</xref></p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>In addition to its established indications, paclitaxel has demonstrated versatility in various off-label uses, showcasing its potential in addressing challenging malignancies, some of which are mentioned below.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Metastatic bladder cancer:</bold> Paclitaxel is used in combination therapy with gemcitabine to treat metastatic or advanced bladder cancer.<xref ref-type="bibr" rid="article-26519.r11">[11]</xref><xref ref-type="bibr" rid="article-26519.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Advanced cervical cancer:</bold> In combination with topotecan, bevacizumab, and/or cisplatin, paclitaxel is used to treat advanced cervical cancer.<xref ref-type="bibr" rid="article-26519.r13">[13]</xref><xref ref-type="bibr" rid="article-26519.r14">[14]</xref><xref ref-type="bibr" rid="article-26519.r15">[15]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Esophageal and gastric cancers:</bold> Paclitaxel plays a crucial role in preoperative management when combined with carboplatin and radiation therapy for patients with esophageal and gastric cancers.<xref ref-type="bibr" rid="article-26519.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Advanced head and neck cancer:</bold> Paclitaxel is utilized in combination with cisplatin for the treatment of advanced head and neck cancer.<xref ref-type="bibr" rid="article-26519.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Neoadjuvant treatment in penile cancer:</bold> Paclitaxel is considered for neoadjuvant therapy in cases of penile cancer with bulky regional lymph node metastases.<xref ref-type="bibr" rid="article-26519.r18">[18]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Relapsed or refractory small-cell&#x000a0;lung cancer:</bold> Paclitaxel is used to treat small-cell lung cancer that has relapsed or proven refractory to other therapies.<xref ref-type="bibr" rid="article-26519.r19">[19]</xref><xref ref-type="bibr" rid="article-26519.r20">[20]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Advanced or unresectable angiosarcoma:</bold> Paclitaxel may be administered to treat advanced or unresectable angiosarcoma.<xref ref-type="bibr" rid="article-26519.r21">[21]</xref><xref ref-type="bibr" rid="article-26519.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Relapsed or refractory testicular germ cell tumors:</bold> Paclitaxel is used in combination with gemcitabine and oxaliplatin or ifosfamide and cisplatin for the treatment of relapsed or refractory testicular germ cell tumors.<xref ref-type="bibr" rid="article-26519.r23">[23]</xref><xref ref-type="bibr" rid="article-26519.r24">[24]</xref><xref ref-type="bibr" rid="article-26519.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Advanced thymoma/thymic carcinoma:</bold> Paclitaxel is combined with carboplatin to treat advanced thymoma/thymic carcinoma.<xref ref-type="bibr" rid="article-26519.r26">[26]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Unknown primary adenocarcinoma:</bold> Paclitaxel, often combined with carboplatin and/or etoposide, is used to treat unknown primary adenocarcinoma cases.<xref ref-type="bibr" rid="article-26519.r27">[27]</xref><xref ref-type="bibr" rid="article-26519.r28">[28]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Endometrial carcinoma:</bold> Paclitaxel finds application in the treatment of endometrial carcinoma.<xref ref-type="bibr" rid="article-26519.r29">[29]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Metastatic or unresectable esophageal and gastric cancers:</bold> Paclitaxel is utilized to address metastatic or unresectable esophageal <xref ref-type="bibr" rid="article-26519.r30">[30]</xref>&#x000a0;and gastric cancers.<xref ref-type="bibr" rid="article-26519.r31">[31]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Melanoma:</bold> Paclitaxel is considered in the treatment of melanoma.<xref ref-type="bibr" rid="article-26519.r32">[32]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Anaplastic thyroid cancer:</bold> Paclitaxel may be used in managing anaplastic thyroid cancer.<xref ref-type="bibr" rid="article-26519.r33">[33]</xref></p>
          </list-item>
        </list>
        <p>These diverse off-label uses underscore paclitaxel's potential as a therapeutic option in various challenging clinical scenarios.</p>
      </sec>
      <sec id="article-26519.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>As an antimicrotubule agent,&#x000a0;paclitaxel promotes the assembly of microtubules, enhances the activity of tubulin dimers, and stabilizes existing microtubules while concurrently inhibiting their disassembly. The increased stability of microtubules in the presence of paclitaxel results in cell cycle arrest at the late G2 phase, leading to inhibition of cell replication. Furthermore, paclitaxel can distort mitotic spindles and lead to chromosome fragmentation.<xref ref-type="bibr" rid="article-26519.r34">[34]</xref></p>
        <p><bold>Microtubules and cell division:</bold> Microtubules are dynamic cytoskeletal structures composed of tubulin protein subunits. They are essential in several cellular processes&#x02014;including cell division&#x02014;mitosis and meiosis. During mitosis, microtubules form a spindle apparatus that separates duplicated chromosomes, ensuring the accurate distribution of genetic material to the resulting daughter cells. This process is essential for maintaining normal cell growth and facilitating tissue repair.</p>
        <p><bold>Microtubule stabilization:</bold>&#x000a0;Paclitaxel functions by binding to the &#x003b2;-tubulin subunits within microtubules. Specifically, paclitaxel binds to the inner surface of microtubules in proximity to the nucleotide-binding site on &#x003b2;-tubulin. This binding promotes the assembly of tubulin subunits into stable, non-dynamic microtubules, effectively impeding their typical disassembly or depolymerization.</p>
        <p><bold>Mitotic spindle formation:</bold> By stabilizing microtubules, paclitaxel disrupts the dynamic equilibrium of microtubule assembly and disassembly, a critical process for the formation and functionality of the mitotic spindle. As a result, the spindle apparatus cannot properly segregate chromosomes during mitosis.</p>
        <p><bold>Cell cycle arrest:</bold> The disruption of proper spindle function triggers a cell cycle checkpoint response, primarily activating the spindle assembly checkpoint (SAC) within the cell cycle. The SAC is a surveillance mechanism that ensures correct alignment and attachment of chromosomes to the spindle before the progression of cell division. In the presence of paclitaxel, the SAC detects anomalies in the spindle formation caused by the stabilized microtubules. This detection results in the cell cycle arrest at the G2/M phase, effectively preventing the cell from advancing into mitosis.</p>
        <p><bold>Induction of apoptosis:</bold> Prolonged arrest in the G2/M phase activates cellular signaling pathways that promote apoptosis. Cells recognize their inability to complete mitosis and, as a protective mechanism, initiate programmed cell death to eliminate damaged or aberrant cells. Consequently, paclitaxel induces apoptosis in cancer cells that have accumulated due to defective cell division.</p>
        <p><bold>Impact on cancer cells:</bold>&#x000a0;Cancer cells, especially those that divide rapidly, exhibit heightened sensitivity to paclitaxel's effects because of their heavy dependence on microtubule dynamics for sustained growth and division. By stabilizing microtubules and disrupting mitotic spindle formation, paclitaxel specifically targets cancer cells and reduces their ability to proliferate.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>The pharmacokinetics of paclitaxel involve rapid intravenous (IV) administration, extensive plasma protein binding, hepatic metabolism, and biliary excretion. A comprehensive understanding of these aspects of paclitaxel's pharmacokinetics is essential for the safe and effective application of this drug in cancer treatment. This knowledge empowers healthcare professionals to customize dosing regimens and effectively manage potential drug interactions or adverse effects.</p>
        <p><bold>Absorption</bold>: Paclitaxel is available in IV formulations, and its absorption phase is bypassed&#x000a0;through direct administration into the bloodstream. The IV infusion ensures rapid and complete distribution of paclitaxel into the systemic circulation.</p>
        <p><bold>Distribution</bold>: After IV administration, paclitaxel undergoes extensive distribution throughout the body, with a volume of distribution of approximately 182 L/m&#x000b2;. Paclitaxel demonstrates a significant degree of plasma protein binding, with approximately 89% to 98% of the drug being bound to plasma proteins, primarily to albumin. The protein binding feature of paclitaxel plays a pivotal role in both its distribution within the body and its elimination from the system.</p>
        <p><bold>Metabolism</bold>: Approximately 90% of paclitaxel is primarily metabolized in the liver by the cytochrome (CYP) P450 enzyme system, particularly involving the CYP2C8 and CYP3A4 isoenzymes. The major metabolic pathway involves hydroxylation of the side chain at the C13 position, forming several metabolites, including 6&#x003b1;-hydroxy paclitaxel and 3'-p-hydroxy paclitaxel. These metabolites are less pharmacologically active than the parent drug.</p>
        <p><bold>Elimination</bold>: The primary route of paclitaxel elimination is hepatic metabolism and biliary excretion. Only a minor fraction of the drug, typically less than 10%, is excreted unchanged in the urine. Paclitaxel and its metabolites undergo elimination from the body with a biphasic decline in plasma concentration. The initial rapid elimination phase has a half-life of about 3 to 14 minutes, followed by a slower terminal phase with a half-life of approximately 13 to 52 hours.</p>
      </sec>
      <sec id="article-26519.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Dosage Form</bold>
</p>
        <p>Patients can receive paclitaxel in an IV formulation.</p>
        <p>
<bold>Strength</bold>
</p>
        <p>The strength of paclitaxel in its IV formulation is 6 mg/mL.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>The infusion duration for paclitaxel typically ranges from 3 to 24 hours, which varies based on the specific indication or treatment protocol.&#x000a0;Certain off-label protocols incorporate a 1-hour infusion, and there are also instances of off-label intraperitoneal use. During paclitaxel infusion, it is recommended to use a 0.22-&#x000b5;m in-line filter and a polyethylene-lined administration set (non-polyvinyl chloride).<xref ref-type="bibr" rid="article-26519.r35">[35]</xref> When paclitaxel is included in a combination chemotherapy regimen, the specific order of administration may vary depending on the regimen being used. Therefore, referring to a protocol for the recommended sequence in such cases is important. Patients may also receive premedication before the infusion, which can include dexamethasone 20 mg PO 12 and 6 hours prior, diphenhydramine 50 mg via IV route 30 to 60 minutes prior, cimetidine 300 mg via IV route, or ranitidine 50 mg via IV route.<xref ref-type="bibr" rid="article-26519.r36">[36]</xref><xref ref-type="bibr" rid="article-26519.r37">[37]</xref><xref ref-type="bibr" rid="article-26519.r38">[38]</xref> Due to paclitaxel's potency as an irritant, caution should be exercised to prevent extravasation. Proper needle and catheter positioning are essential during the administration of this medication.&#x000a0;</p>
        <table-wrap id="article-26519.table1" position="float" orientation="portrait">
          <table style="width: 790px;" border="1" cellspacing="1" cellpadding="5">
            <tbody>
              <tr style="height: 35px;">
                <td style="height: 35px;" rowspan="1" colspan="1">
<bold>Indications</bold>
</td>
                <td style="height: 35px;" rowspan="1" colspan="1">
<p><bold>Dosage</bold></p>
</td>
              </tr>
              <tr style="height: 94.5px;">
                <td style="height: 94.5px;" rowspan="1" colspan="1">Ovarian cancer</td>
                <td style="height: 94.5px;" rowspan="1" colspan="1">
<p>Previously treated patients: The recommended&#x000a0;dosage may range between 135 and 175 mg/m&#x000b2; of paclitaxel administered via IV route over 3 hours every 3 weeks.</p>
<p>Previously untreated patients:&#x000a0;The recommended dosage options of&#x000a0;paclitaxel via IV route are 175 mg/m&#x000b2; administered over 3 hours every 3 weeks to be followed by cisplatin, or 135 mg/m&#x000b2; administered over 24 hours every 3 weeks and also followed by cisplatin.</p>
</td>
              </tr>
              <tr style="height: 27px;">
                <td style="height: 27px;" rowspan="1" colspan="1">NSCLC</td>
                <td style="height: 27px;" rowspan="1" colspan="1">The&#x000a0;recommended&#x000a0;dosage is 135 mg/m&#x000b2; of paclitaxel administered via IV route over a 24-hour period every 3 weeks to be followed by cisplatin.</td>
              </tr>
              <tr style="height: 87px;">
                <td style="height: 87px;" rowspan="1" colspan="1">Breast cancer</td>
                <td style="height: 87px;" rowspan="1" colspan="1">
<p>Adjuvant treatment: The&#x000a0;recommended&#x000a0;dosage is 175 mg/m&#x000b2; of paclitaxel administered via IV route over 3 hours every 3 weeks for a total of 4 cycles.</p>
<p>Metastatic treatment:&#x000a0;The&#x000a0;recommended&#x000a0;dosage is&#x000a0;175 mg/m&#x000b2; of paclitaxel&#x000a0;administered via IV route&#x000a0;over 3 hours every 3 weeks.</p>
</td>
              </tr>
              <tr style="height: 27px;">
                <td style="height: 27px;" rowspan="1" colspan="1">AIDS-related Kaposi sarcoma</td>
                <td style="height: 27px;" rowspan="1" colspan="1">The recommended dosage options of paclitaxel administered via IV route are either 135 mg/m&#x000b2; over 24 hours every 3 weeks or 100 mg/m&#x000b2; over 3 hours every 2 weeks.</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Renal impairment</bold>: Paclitaxel and its metabolites are predominantly eliminated through hepatic metabolism, with only a minor portion excreted unchanged in the urine. Consequently, dosage adjustments are typically unnecessary for patients with mild-to-moderate renal impairment.</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;Hepatic impairment can influence the metabolism and elimination of paclitaxel, which may result in elevated exposure to the drug and its metabolites. As a result, dosage adjustments may be necessary for patients with moderate-to-severe hepatic impairment. In patients with solid carcinomas, excluding Kaposi sarcoma, paclitaxel dosage should be adjusted according to the patient's aspartate transaminase/alanine transaminase (AST/ALT) and bilirubin levels. For instance, in the case of a 24-hour infusion, when the patient's AST/ALT is less than 10 times the upper limit of normal (ULN) and their bilirubin falls within the range of 1.6 to 7.5 mg/dL, the suggested paclitaxel dose is 50 mg/m&#x000b2; administered over 24 hours.</p>
        <table-wrap id="article-26519.table2" position="float" orientation="portrait">
          <table style="width: 790px;" border="1" cellspacing="1" cellpadding="5">
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">
<bold>3-Hour Infusion</bold>
</td>
                <td rowspan="1" colspan="1">
<bold>24-Hour Infusion</bold>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>AST/ALT &#x0003c;10 x ULN and bilirubin &#x0003c;1.25 x ULN: 175 mg/m&#x000b2; over 3 h</p></list-item><list-item><p>AST/ALT &#x0003c;10 x ULN and bilirubin 1.26-2 x ULN: 135 mg/m&#x000b2; over 3 h</p></list-item><list-item><p>AST/ALT &#x0003c;10 x ULN and bilirubin 2.01-5 x ULN: 90 mg/m&#x000b2; over 3 h</p></list-item><list-item><p>AST/ALT &#x02265;10 x ULN or bilirubin &#x0003e;5 x ULN: Do not administer.</p></list-item></list>
</td>
                <td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>AST/ALT &#x0003c;2 x ULN and bilirubin &#x02264;1.5 mg/dL: 135 mg/m&#x000b2; over 24 h</p></list-item><list-item><p>AST/ALT 2-&#x0003c;10 x ULN and bilirubin &#x02264;1.5 mg/dL: 100 mg/m&#x000b2; over 24 h</p></list-item><list-item><p>AST/ALT &#x0003c;10 x ULN and bilirubin 1.6 to 7.5 mg/dL: 50 mg/m&#x000b2; over 24 h</p></list-item><list-item><p>AST/ALT &#x02265;10 x ULN or bilirubin &#x0003e;7.5 mg/dL: Do not administer.</p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p><bold>Pregnancy considerations</bold>: Paclitaxel is categorized as a pregnancy category D drug, which signifies a potential risk to the fetus, as inferred from the data obtained from animal and human studies. The use of the drug&#x000a0;during pregnancy should only be considered when the potential benefits outweigh the possible risks to the fetus. Notably, insufficient data is available for this specific human population.</p>
        <p><bold>Breastfeeding considerations</bold>: The use of paclitaxel during breastfeeding is not recommended due to the potential for the drug to be excreted into breast milk, which could potentially harm the nursing infant.</p>
        <p><bold>Pediatric patients</bold>: Paclitaxel is infrequently utilized in pediatric populations due to the limited clinical data and the availability of alternative cancer treatments. The safety and efficacy of paclitaxel in children have not been firmly established.</p>
        <p><bold>Older patients</bold>: Using paclitaxel in elderly patients requires careful assessment of their comprehensive health status, organ function, and any existing comorbidities. Older patients may exhibit increased susceptibility to drug-related toxicities due to age-related changes in drug metabolism and clearance. Dosage adjustments and individualized treatment plans may be essential to mitigate potential adverse effects, including myelosuppression, while preserving treatment effectiveness.</p>
      </sec>
      <sec id="article-26519.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Paclitaxel can cause a range of&#x000a0;adverse effects.&#x000a0;The most prevalent adverse effects&#x000a0;of paclitaxel use are alopecia, nausea and vomiting, mucositis, neutropenia, leukopenia, anemia, hypersensitivity reactions, arthralgia, myalgia, and weakness. Peripheral neuropathy is another common&#x000a0;adverse&#x000a0;effect, and patients with preexisting neuropathies may have an increased risk. A 20% reduction in the dose should be considered for patients who develop severe neuropathy.<xref ref-type="bibr" rid="article-26519.r39">[39]</xref></p>
        <p>Less frequently reported adverse effects include flushing, edema, hypotension, skin rash, stomatitis, thrombocytopenia, hemorrhage, increased serum alkaline phosphatase and AST, local injection site reaction, and increased serum creatinine. Injection site reactions are typically mild and characterized by symptoms such as erythema, tenderness, skin discoloration, or swelling. Extended infusion durations, such as 24 hours, increase the likelihood of their occurrence.&#x000a0;Notably,&#x000a0;delays of injection site reactions can extend from 7 to 10 days. Patients may also experience infusion-related hypotension, bradycardia, and hypertension. Consequently, it is advisable to regularly monitor the patient's vital signs, particularly during the initial hour of the infusion.<xref ref-type="bibr" rid="article-26519.r40">[40]</xref>&#x000a0;</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Paclitaxel can interact with several other medications. Paclitaxel has 422 known drug interactions, categorized as 49 major, 356 moderate, and 17 minor. The essential details on the drug-drug interactions associated with paclitaxel are mentioned below.</p>
        <p><bold>Cytochrome P450 enzymes</bold>: Paclitaxel undergoes primary metabolism through the cytochrome P450 (CYP) enzyme system, specifically CYP2C8 and CYP3A4. Drugs that either inhibit or induce these enzymes can alter the metabolism and clearance of paclitaxel.</p>
        <list list-type="bullet">
          <list-item>
            <p>Inhibitors of CYP2C8 and CYP3A4: Drugs such as ketoconazole, erythromycin, clarithromycin, fluoxetine, and grapefruit juice can inhibit CYP2C8 and CYP3A4. This inhibition can result in elevated plasma concentrations, potentially increasing the risk of paclitaxel-related&#x000a0;toxicities.</p>
          </list-item>
          <list-item>
            <p>Inducers of CYP2C8 and CYP3A4: Drugs such as rifampin, phenytoin, carbamazepine, and St John's wort can induce CYP2C8 and CYP3A4. This induction can lead to diminished paclitaxel plasma concentrations, potentially compromising its efficacy.</p>
          </list-item>
        </list>
        <p><bold>P-glycoprotein (P-gp) and other efflux transporters</bold>: Paclitaxel is a substrate of P-gp, an efflux transporter present in various tissues, including the blood-brain barrier and the gastrointestinal tract. Drugs that either inhibit or induce P-gp can alter the distribution and elimination of paclitaxel.</p>
        <list list-type="bullet">
          <list-item>
            <p>Inhibitors of P-gp: Drugs such as verapamil, quinidine, and amiodarone can inhibit P-gp, resulting in heightened systemic exposure to paclitaxel and the potential for toxicities.</p>
          </list-item>
          <list-item>
            <p>Inducers of P-gp: Drugs such as rifampin and carbamazepine can induce P-gp, potentially reducing paclitaxel plasma concentrations and efficacy.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26519.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Paclitaxel should not be administered to patients who have experienced a severe hypersensitivity reaction to paclitaxel or any of its excipients.</p>
        <p>For patients with solid tumors, paclitaxel should be avoided if their baseline neutrophil count is below 1500 cells/mm&#x000b3;. In the case of AIDS-related Kaposi sarcoma, paclitaxel is not recommended if the baseline neutrophil count falls below 1000 cells/mm&#x000b3;. Bone marrow suppression depends on the paclitaxel dose and represents a limitation in dosing due to its potential for toxicity. In the event of bone marrow suppression, subsequent doses should be decreased by 20%, especially for severe neutropenia, and supportive therapy should be considered, such as growth factor treatment.<xref ref-type="bibr" rid="article-26519.r41">[41]</xref></p>
        <p>
<bold>Black Box Warnings and Precautions</bold>
</p>
        <p>Paclitaxel has a black box warning for hypersensitivity reactions and bone marrow suppression. Before the infusion, patients should receive premedication with corticosteroids, diphenhydramine, and H2 antagonists to prevent anaphylaxis and severe hypersensitivity reactions. The suggested regimen includes dexamethasone at 20 mg administered via IV route or orally 12 and 6 hours before the paclitaxel dose, with a reduced dosage of 10 mg for patients with advanced HIV. Diphenhydramine, at a dosage of 50 mg IV, should be administered 30 to 60 minutes before the paclitaxel dose. Cimetidine 300 mg, famotidine 20 mg, or ranitidine 50 mg are all suitable options for IV administration 30 to 60 minutes before the paclitaxel dose. Severe hypersensitivity reactions include dyspnea requiring bronchodilators, hypotension requiring treatment, angioedema, and/or generalized urticaria. In situations involving a severe hypersensitivity reaction, stopping the infusion and discontinuing paclitaxel is imperative. Minor hypersensitivity reactions, which include&#x000a0;flushing, dyspnea, hypotension, skin reactions, or tachycardia, generally do not necessitate interruption or discontinuation of the treatment.<xref ref-type="bibr" rid="article-26519.r42">[42]</xref><xref ref-type="bibr" rid="article-26519.r43">[43]</xref></p>
      </sec>
      <sec id="article-26519.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The infusion site should be monitored for extravasation. In case of extravasation, healthcare providers should promptly halt and disconnect the infusion but retain the needle or cannula in its position. The extravasated solution should be gently aspirated while avoiding flushing the line.&#x000a0;Following this, the healthcare provider should remove the needle or cannula, administer the antidote, discard the used needle or cannula, and elevate the extremity. However,&#x000a0;conflicting data exist regarding the use of warm or cold compresses.<xref ref-type="bibr" rid="article-26519.r44">[44]</xref>&#x000a0;Patients should also be monitored for developing a severe hypersensitivity reaction. Although every patient should receive premedication to prevent the occurrence of a hypersensitivity reaction, some patients may still experience one that necessitates the discontinuation of treatment.</p>
        <p><bold>Monitoring Paclitaxel Resistance</bold>&#x000a0;</p>
        <p>Paclitaxel resistance is a significant cause of treatment failure and tumor progression. Several mechanisms have been associated with paclitaxel resistance, as mentioned below.</p>
        <p><bold>Overexpression of drug efflux pumps:</bold> One of the primary mechanisms of paclitaxel resistance involves the upregulation of ATP-binding cassette (ABC) transporters, including P-gp, multidrug resistance protein 1 (MRP1), and breast cancer resistance protein (BCRP). These transporters actively pump paclitaxel out of the cancer cells, reducing its intracellular concentration and, consequently, its cytotoxic effect.</p>
        <p><bold>Alteration of microtubule structure:</bold>&#x000a0;Paclitaxel exerts its cytotoxic effect by stabilizing microtubules, which results in mitotic arrest and eventual cell death. Resistance can arise due to modifications in tubulin expression or mutations in tubulin genes, resulting in alterations in microtubule structure that render them less responsive to paclitaxel's stabilizing properties.</p>
        <p><bold>Enhanced DNA repair mechanisms:</bold> Paclitaxel-induced DNA damage can trigger cell death pathways. However, cancer cells that have developed resistance may upregulate DNA repair mechanisms, allowing them to repair the DNA damage caused by the drug and survive the cytotoxic effects of paclitaxel.</p>
        <p><bold>Activation of survival pathways:</bold>&#x000a0;The cellular stress induced by paclitaxel can activate survival pathways, including PI3K/AKT and MAPK/ERK, which promote cell survival and reduce sensitivity to paclitaxel-induced apoptosis in resistant cancer cells.</p>
        <p><bold>Altered apoptosis signaling:</bold> Paclitaxel-induced apoptosis is a crucial mechanism of cancer cell death. Paclitaxel resistance may arise from alterations in the apoptotic signaling pathway, preventing cancer cells from undergoing programmed cell death in response to the drug. Numerous critical genes in this context include <italic toggle="yes">bcl-2</italic>, <italic toggle="yes">bcl-x</italic>, and <italic toggle="yes">p53</italic>.</p>
      </sec>
      <sec id="article-26519.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Currently, no known antidote for paclitaxel overdosage exists. The primary expected complications of overdosage would typically involve bone marrow suppression, peripheral neurotoxicity, and mucositis. However, it is noteworthy that hyaluronidase is commonly utilized as an antidote for addressing paclitaxel extravasation. If the needle or cannula is still in place, it is advised to administer 1 to 6&#x000a0;mL&#x000a0;of hyaluronidase into the existing IV line. If the needle or cannula is no longer inserted, healthcare providers may inject the hyaluronidase subcutaneously, encircling the area of extravasation clockwise. This procedure may be repeated several times over the next 3 to 4 hours.<xref ref-type="bibr" rid="article-26519.r45">[45]</xref></p>
      </sec>
      <sec id="article-26519.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Effective interprofessional teamwork and communication are vital to ensure that all patients receive their prescribed dose and regimen in accordance with FDA guidelines or hospital protocols. Oncologists should comprehensively evaluate a patient and choose an appropriate treatment regimen based on the specific guidelines and patient-specific factors. The nursing staff&#x000a0;should receive proper training on recognizing the signs and symptoms of hypersensitivity reactions to paclitaxel, and they should be well versed in the management of extravasation incidents. Pharmacists should assess the patient's current and complete drug regimen. They should also ensure there are no drug interactions, as paclitaxel has many potential interactions that could necessitate treatment modifications. These are just a few examples of healthcare professionals who may have responsibilities when caring for patients receiving paclitaxel. Notably, each healthcare professional&#x000a0;contributes significantly toward a patient's overall well-being, despite some overlap in their roles and across various interprofessional healthcare professions.</p>
      </sec>
      <sec id="article-26519.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26519&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26519">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/26519/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=26519">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-26519.s11">
        <title>References</title>
        <ref id="article-26519.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McGuire</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Hoskins</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Brady</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Kucera</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Partridge</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Look</surname>
                <given-names>KY</given-names>
              </name>
              <name>
                <surname>Clarke-Pearson</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group study.</article-title>
            <source>Semin Oncol</source>
            <year>1997</year>
            <month>Feb</month>
            <volume>24</volume>
            <issue>1 Suppl 2</issue>
            <fpage>S2</fpage>
            <page-range>S2-13-S2-16</page-range>
            <pub-id pub-id-type="pmid">9045329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Armstrong</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Bundy</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wenzel</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>HQ</given-names>
              </name>
              <name>
                <surname>Baergen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lele</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Copeland</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Burger</surname>
                <given-names>RA</given-names>
              </name>
              <collab>Gynecologic Oncology Group</collab>
            </person-group>
            <article-title>Intraperitoneal cisplatin and paclitaxel in ovarian cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2006</year>
            <month>Jan</month>
            <day>05</day>
            <volume>354</volume>
            <issue>1</issue>
            <fpage>34</fpage>
            <page-range>34-43</page-range>
            <pub-id pub-id-type="pmid">16394300</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nardi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aloe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De Marco</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cognetti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Iacovelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Atlante</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Calabresi</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a phase II study.</article-title>
            <source>Am J Clin Oncol</source>
            <year>1997</year>
            <month>Jun</month>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>230</fpage>
            <page-range>230-2</page-range>
            <pub-id pub-id-type="pmid">9167742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mayerhofer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kucera</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zeisler</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Speiser</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Reinthaller</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sevelda</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy.</article-title>
            <source>Gynecol Oncol</source>
            <year>1997</year>
            <month>Jan</month>
            <volume>64</volume>
            <issue>1</issue>
            <fpage>109</fpage>
            <page-range>109-13</page-range>
            <pub-id pub-id-type="pmid">8995557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loesch</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Greco</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Senzer</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Burris</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Hainsworth</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vukelja</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Sandbach</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sedlacek</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pippen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lindquist</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>McIntyre</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Blum</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Modiano</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Boehm</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Zhan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Asmar</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Robert</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer.</article-title>
            <source>J Clin Oncol</source>
            <year>2010</year>
            <month>Jun</month>
            <day>20</day>
            <volume>28</volume>
            <issue>18</issue>
            <fpage>2958</fpage>
            <page-range>2958-65</page-range>
            <pub-id pub-id-type="pmid">20479419</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akerley</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Sikov</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Cummings</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Safran</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Strenger</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Marchant</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report.</article-title>
            <source>Semin Oncol</source>
            <year>1997</year>
            <month>Oct</month>
            <volume>24</volume>
            <issue>5 Suppl 17</issue>
            <fpage>S17</fpage>
            <page-range>S17-87-S17-90</page-range>
            <pub-id pub-id-type="pmid">9374102</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hande</surname>
                <given-names>KR</given-names>
              </name>
            </person-group>
            <article-title>Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial.</article-title>
            <source>Semin Oncol</source>
            <year>1997</year>
            <month>Feb</month>
            <volume>24</volume>
            <issue>1 Suppl 3</issue>
            <fpage>S22</fpage>
            <page-range>S22-5</page-range>
            <pub-id pub-id-type="pmid">9071336</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Panagos</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <article-title>Treatment of advanced and relapsing breast cancer with a combination of paclitaxel and mitoxantrone. South-Central Hellenic Oncology Group.</article-title>
            <source>Semin Oncol</source>
            <year>1997</year>
            <month>Feb</month>
            <volume>24</volume>
            <issue>1 Suppl 3</issue>
            <fpage>S17</fpage>
            <page-range>S17-21</page-range>
            <pub-id pub-id-type="pmid">9071335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ohe</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ohashi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kubota</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tamura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakagawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Negoro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nishiwaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Saijo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ariyoshi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fukuoka</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.</article-title>
            <source>Ann Oncol</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>317</fpage>
            <page-range>317-23</page-range>
            <pub-id pub-id-type="pmid">17079694</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gill</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Tulpule</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Espina</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Cabriales</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bresnahan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ilaw</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Louie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gustafson</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Orcutt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Winograd</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Scadden</surname>
                <given-names>DT</given-names>
              </name>
            </person-group>
            <article-title>Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma.</article-title>
            <source>J Clin Oncol</source>
            <year>1999</year>
            <month>Jun</month>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>1876</fpage>
            <page-range>1876-83</page-range>
            <pub-id pub-id-type="pmid">10561228</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meluch</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Greco</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Burris</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>O'Rourke</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ortega</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Steis</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Morrissey</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hainsworth</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network.</article-title>
            <source>J Clin Oncol</source>
            <year>2001</year>
            <month>Jun</month>
            <day>15</day>
            <volume>19</volume>
            <issue>12</issue>
            <fpage>3018</fpage>
            <page-range>3018-24</page-range>
            <pub-id pub-id-type="pmid">11408496</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sternberg</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Calabr&#x000f2;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pizzocaro</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Marini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Schnetzer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sella</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.</article-title>
            <source>Cancer</source>
            <year>2001</year>
            <month>Dec</month>
            <day>15</day>
            <volume>92</volume>
            <issue>12</issue>
            <fpage>2993</fpage>
            <page-range>2993-8</page-range>
            <pub-id pub-id-type="pmid">11753976</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tewari</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Sill</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Penson</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ramondetta</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Landrum</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Oaknin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Leitao</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Michael</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Monk</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Improved survival with bevacizumab in advanced cervical cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2014</year>
            <month>Feb</month>
            <day>20</day>
            <volume>370</volume>
            <issue>8</issue>
            <fpage>734</fpage>
            <page-range>734-43</page-range>
            <pub-id pub-id-type="pmid">24552320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Monk</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Sill</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>McMeekin</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Cohn</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Ramondetta</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Boardman</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Benda</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cella</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.</article-title>
            <source>J Clin Oncol</source>
            <year>2009</year>
            <month>Oct</month>
            <day>01</day>
            <volume>27</volume>
            <issue>28</issue>
            <fpage>4649</fpage>
            <page-range>4649-55</page-range>
            <pub-id pub-id-type="pmid">19720909</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moore</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Blessing</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>McQuellon</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Thaler</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Cella</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Benda</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Olt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Boggess</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Rocereto</surname>
                <given-names>TF</given-names>
              </name>
            </person-group>
            <article-title>Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study.</article-title>
            <source>J Clin Oncol</source>
            <year>2004</year>
            <month>Aug</month>
            <day>01</day>
            <volume>22</volume>
            <issue>15</issue>
            <fpage>3113</fpage>
            <page-range>3113-9</page-range>
            <pub-id pub-id-type="pmid">15284262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Hagen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hulshof</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>van Lanschot</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Steyerberg</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>van Berge Henegouwen</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Wijnhoven</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Richel</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Nieuwenhuijzen</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Hospers</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Bonenkamp</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Cuesta</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Blaisse</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Busch</surname>
                <given-names>OR</given-names>
              </name>
              <name>
                <surname>ten Kate</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Creemers</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Punt</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Plukker</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Verheul</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Spillenaar Bilgen</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>van Dekken</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>van der Sangen</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Rozema</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Biermann</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Beukema</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Piet</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>van Rij</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Reinders</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Tilanus</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>van der Gaast</surname>
                <given-names>A</given-names>
              </name>
              <collab>CROSS Group</collab>
            </person-group>
            <article-title>Preoperative chemoradiotherapy for esophageal or junctional cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2012</year>
            <month>May</month>
            <day>31</day>
            <volume>366</volume>
            <issue>22</issue>
            <fpage>2074</fpage>
            <page-range>2074-84</page-range>
            <pub-id pub-id-type="pmid">22646630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gibson</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hussain</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>DeConti</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Ensley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Forastiere</surname>
                <given-names>AA</given-names>
              </name>
              <collab>Eastern Cooperative Oncology Group</collab>
            </person-group>
            <article-title>Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.</article-title>
            <source>J Clin Oncol</source>
            <year>2005</year>
            <month>May</month>
            <day>20</day>
            <volume>23</volume>
            <issue>15</issue>
            <fpage>3562</fpage>
            <page-range>3562-7</page-range>
            <pub-id pub-id-type="pmid">15908667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pagliaro</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Daliani</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Osai</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kincaid</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thall</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Pettaway</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study.</article-title>
            <source>J Clin Oncol</source>
            <year>2010</year>
            <month>Aug</month>
            <day>20</day>
            <volume>28</volume>
            <issue>24</issue>
            <fpage>3851</fpage>
            <page-range>3851-7</page-range>
            <pub-id pub-id-type="pmid">20625118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smit</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Fokkema</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Biesma</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Groen</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Snoek</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Postmus</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer.</article-title>
            <source>Br J Cancer</source>
            <year>1998</year>
            <volume>77</volume>
            <issue>2</issue>
            <fpage>347</fpage>
            <page-range>347-51</page-range>
            <pub-id pub-id-type="pmid">9461009</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamamoto</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tsurutani</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yoshimura</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Asai</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Moriyama</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nakagawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kudoh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Takada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Minato</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fukuoka</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer.</article-title>
            <source>Anticancer Res</source>
            <year>2006</year>
            <season>Jan-Feb</season>
            <volume>26</volume>
            <issue>1B</issue>
            <fpage>777</fpage>
            <page-range>777-81</page-range>
            <pub-id pub-id-type="pmid">16739353</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Penel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bui</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Bay</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Cupissol</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ray-Coquard</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Piperno-Neumann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kerbrat</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fournier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Taieb</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jimenez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Isambert</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Peyrade</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chevreau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bompas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Brain</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Blay</surname>
                <given-names>JY</given-names>
              </name>
            </person-group>
            <article-title>Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.</article-title>
            <source>J Clin Oncol</source>
            <year>2008</year>
            <month>Nov</month>
            <day>10</day>
            <volume>26</volume>
            <issue>32</issue>
            <fpage>5269</fpage>
            <page-range>5269-74</page-range>
            <pub-id pub-id-type="pmid">18809609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schlemmer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reichardt</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Verweij</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hartmann</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Judson</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Thyss</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hogendoorn</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Marreaud</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Van Glabbeke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Blay</surname>
                <given-names>JY</given-names>
              </name>
            </person-group>
            <article-title>Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group.</article-title>
            <source>Eur J Cancer</source>
            <year>2008</year>
            <month>Nov</month>
            <volume>44</volume>
            <issue>16</issue>
            <fpage>2433</fpage>
            <page-range>2433-6</page-range>
            <pub-id pub-id-type="pmid">18771914</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bokemeyer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Oechsle</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Honecker</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hartmann</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Waller</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>B&#x000f6;hlke</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kollmannsberger</surname>
                <given-names>C</given-names>
              </name>
              <collab>German Testicular Cancer Study Group</collab>
            </person-group>
            <article-title>Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group.</article-title>
            <source>Ann Oncol</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>448</fpage>
            <page-range>448-53</page-range>
            <pub-id pub-id-type="pmid">18006893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kondagunta</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Bacik</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Donadio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bajorin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Marion</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sheinfeld</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bosl</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Motzer</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors.</article-title>
            <source>J Clin Oncol</source>
            <year>2005</year>
            <month>Sep</month>
            <day>20</day>
            <volume>23</volume>
            <issue>27</issue>
            <fpage>6549</fpage>
            <page-range>6549-55</page-range>
            <pub-id pub-id-type="pmid">16170162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Einhorn</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Brames</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Juliar</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant.</article-title>
            <source>J Clin Oncol</source>
            <year>2007</year>
            <month>Feb</month>
            <day>10</day>
            <volume>25</volume>
            <issue>5</issue>
            <fpage>513</fpage>
            <page-range>513-6</page-range>
            <pub-id pub-id-type="pmid">17290059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lemma</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Aisner</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Langer</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Tester</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Loehrer</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma.</article-title>
            <source>J Clin Oncol</source>
            <year>2011</year>
            <month>May</month>
            <day>20</day>
            <volume>29</volume>
            <issue>15</issue>
            <fpage>2060</fpage>
            <page-range>2060-5</page-range>
            <pub-id pub-id-type="pmid">21502559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Briasoulis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kalofonos</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bafaloukos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Samantas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fountzilas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Xiros</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Skarlos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Christodoulou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kosmidis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pavlidis</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study.</article-title>
            <source>J Clin Oncol</source>
            <year>2000</year>
            <month>Sep</month>
            <volume>18</volume>
            <issue>17</issue>
            <fpage>3101</fpage>
            <page-range>3101-7</page-range>
            <pub-id pub-id-type="pmid">10963638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greco</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Burris</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Erland</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Kalman</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Schreeder</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Hainsworth</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Carcinoma of unknown primary site.</article-title>
            <source>Cancer</source>
            <year>2000</year>
            <month>Dec</month>
            <day>15</day>
            <volume>89</volume>
            <issue>12</issue>
            <fpage>2655</fpage>
            <page-range>2655-60</page-range>
            <pub-id pub-id-type="pmid">11135228</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rose</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moslemi-Kebria</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Simpkins</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma.</article-title>
            <source>Int J Gynecol Cancer</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>452</fpage>
            <page-range>452-458</page-range>
            <pub-id pub-id-type="pmid">28187088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Noronha</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Patil</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bhosale</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Joshi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Purandare</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Prabhash</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Metronomic weekly paclitaxel in advanced unresectable esophageal cancer.</article-title>
            <source>Indian J Cancer</source>
            <year>2013</year>
            <season>Apr-Jun</season>
            <volume>50</volume>
            <issue>2</issue>
            <fpage>128</fpage>
            <page-range>128-34</page-range>
            <pub-id pub-id-type="pmid">23979204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bozkurt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Amlashi</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Blum Murphy</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The role of chemotherapy in unresectable or metastatic adenocarcinoma of the stomach and gastroesophageal junction.</article-title>
            <source>Minerva Chir</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>72</volume>
            <issue>4</issue>
            <fpage>317</fpage>
            <page-range>317-333</page-range>
            <pub-id pub-id-type="pmid">28415835</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zheng</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Impact of carboplatin plus paclitaxel combined with endostar against A375 melanoma cells: An in vitro and in vivo analysis.</article-title>
            <source>Biomed Pharmacother</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>83</volume>
            <fpage>1321</fpage>
            <page-range>1321-1326</page-range>
            <pub-id pub-id-type="pmid">27571875</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Onoda</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sugino</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Higashiyama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kammori</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Toda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Suganuma</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nakashima</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tsukahara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Noguchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Koizumi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nemoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hara</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Miyauchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sugitani</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>The Safety and Efficacy of Weekly Paclitaxel Administration for Anaplastic Thyroid Cancer Patients: A Nationwide Prospective Study.</article-title>
            <source>Thyroid</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>26</volume>
            <issue>9</issue>
            <fpage>1293</fpage>
            <page-range>1293-9</page-range>
            <pub-id pub-id-type="pmid">27484330</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manfredi</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Horwitz</surname>
                <given-names>SB</given-names>
              </name>
            </person-group>
            <article-title>Taxol: an antimitotic agent with a new mechanism of action.</article-title>
            <source>Pharmacol Ther</source>
            <year>1984</year>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>83</fpage>
            <page-range>83-125</page-range>
            <pub-id pub-id-type="pmid">6149569</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trissel</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Pharmaceutical properties of paclitaxel and their effects on preparation and administration.</article-title>
            <source>Pharmacotherapy</source>
            <year>1997</year>
            <season>Sep-Oct</season>
            <volume>17</volume>
            <issue>5 Pt 2</issue>
            <fpage>133S</fpage>
            <page-range>133S-139S</page-range>
            <pub-id pub-id-type="pmid">9322880</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Toiyama</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Konishi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mohri</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tonouchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Miki</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kusunoki</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Administration sequence-dependent antitumor effects of paclitaxel and 5-fluorouracil in the human gastric cancer cell line MKN45.</article-title>
            <source>Cancer Chemother Pharmacol</source>
            <year>2006</year>
            <month>Feb</month>
            <volume>57</volume>
            <issue>3</issue>
            <fpage>368</fpage>
            <page-range>368-75</page-range>
            <pub-id pub-id-type="pmid">16075279</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheng</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>An</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>XC</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>YF</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>ZH</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>QX</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>YL</given-names>
              </name>
            </person-group>
            <article-title>In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines.</article-title>
            <source>Cancer Chemother Pharmacol</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>67</volume>
            <issue>3</issue>
            <fpage>637</fpage>
            <page-range>637-46</page-range>
            <pub-id pub-id-type="pmid">20495920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saad</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Najjar</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Alashari</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and timing of administration.</article-title>
            <source>J Biochem Mol Toxicol</source>
            <year>2004</year>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>78</fpage>
            <page-range>78-86</page-range>
            <pub-id pub-id-type="pmid">15122649</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brewer</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dolan</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Fleming</surname>
                <given-names>GF</given-names>
              </name>
            </person-group>
            <article-title>Chemotherapy-induced peripheral neuropathy: Current status and progress.</article-title>
            <source>Gynecol Oncol</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>140</volume>
            <issue>1</issue>
            <fpage>176</fpage>
            <page-range>176-83</page-range>
            <pub-id pub-id-type="pmid">26556766</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marupudi</surname>
                <given-names>NI</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Renard</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Tyler</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Brem</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Paclitaxel: a review of adverse toxicities and novel delivery strategies.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>609</fpage>
            <page-range>609-21</page-range>
            <pub-id pub-id-type="pmid">17877447</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ding</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>WM</given-names>
              </name>
            </person-group>
            <article-title>[Analysis of relative factors of bone marrow suppression after chemotherapy with carboplatin and paclitaxel on the patients with ovarian cancer].</article-title>
            <source>Zhonghua Fu Chan Ke Za Zhi</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>46</volume>
            <issue>3</issue>
            <fpage>188</fpage>
            <page-range>188-92</page-range>
            <pub-id pub-id-type="pmid">21575452</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morgan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tillett</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Braybrooke</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ajithkumar</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Management of uncommon chemotherapy-induced emergencies.</article-title>
            <source>Lancet Oncol</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>12</volume>
            <issue>8</issue>
            <fpage>806</fpage>
            <page-range>806-14</page-range>
            <pub-id pub-id-type="pmid">21276754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Banerji</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lax</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Guyer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hurwitz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Camargo</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Management of hypersensitivity reactions to Carboplatin and Paclitaxel in an outpatient oncology infusion center: a 5-year review.</article-title>
            <source>J Allergy Clin Immunol Pract</source>
            <year>2014</year>
            <season>Jul-Aug</season>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>428</fpage>
            <page-range>428-33</page-range>
            <pub-id pub-id-type="pmid">25017531</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>P&#x000e9;rez Fidalgo</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a Fabregat</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cervantes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Margulies</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vidall</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Roila</surname>
                <given-names>F</given-names>
              </name>
              <collab>ESMO Guidelines Working Group</collab>
            </person-group>
            <article-title>Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines.</article-title>
            <source>Ann Oncol</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>23 Suppl 7</volume>
            <fpage>vii167</fpage>
            <page-range>vii167-73</page-range>
            <pub-id pub-id-type="pmid">22997449</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26519.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ener</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Meglathery</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Styler</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Extravasation of systemic hemato-oncological therapies.</article-title>
            <source>Ann Oncol</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>858</fpage>
            <page-range>858-62</page-range>
            <pub-id pub-id-type="pmid">15151940</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
